PubMed Health⌕ Search

Biomedical subjects

G Laurberg

Publications and source records attributed to G Laurberg.

32 records · Page 2Linked to original sources
PubMed1988

Natural and Chang liver cell cytotoxic studies of methotrexate-treated psoriatic patients with liver cirrhosis.

Forty patients with psoriasis were investigated for unspecific and specific lymphocyte cytotoxicity in order to evaluate the significance for liver cell damage in methotrexate-treated (MTX) patients. We found no difference between psoriasis patients with regard to cytotoxicity. We also observed a normal proliferation of lymphocytes after stimulation with tuberculin and phytohemagglutinin.

Adolescent↗
PubMed1987

Bone changes in children on long-term treatment with etretinate.

Ten children with disorders of keratinization (ichthyosis, 4, pityriasis rubra pilaris, 2, psoriasis, 2, and palmoplantar keratoderma, 2) were treated with etretinate for 0.5 to 9.6 years. The children ranged from 1.5 to 15.7 years of age. The total dose of etretinate ranged from 700 to 52,596 mg and the maintenance dose, from 0.21 to 0.86 mg/kg/day. Radiographic skeletal surveys were performed at various stages during treatment or following treatment. Bone abnormalities were found in eight children. Six children had periosteal thickening, two periosteal bone resorption, two osteoporosis, three disc narrowing, and one slender long bones. Compared with age- and sex-matched normal controls, the children had decreased cortical bone thickness of the second left metacarpal bone. The children's physical growth and laboratory investigations were normal. We recommend that children on long-term etretinate therapy be investigated regularly for bone changes.

Adolescent↗
PubMed1983

A randomized trial of etretinate (Tigason) in palmoplantar pustulosis.

5 patients with palmoplantar pustulosis (PPP) were randomized to 8 weeks of daily treatment with either oral etretinate, 1 mg/kg b.w. or placebo. Good or moderate effect was obtained in 18 or 20 patients on etretinate compared o 6 of 21 patients on placebo (p less than 0.001). Etretinate proved to be significantly superior to placebo with regard to influence on the individual symptoms and signs of pustulosis. All patients on etretinate experienced some side effects from the mucous membranes, but they were generally mild. Treatment was discontinued after 4 weeks in 3 patients for reasons unrelated to treatment, in 4 for lack of effect (all on placebo) and in 2 for side effects (both or etretinate). Etretinate is a good alternative to other systemic treatments of PPP.

Adult↗
PubMed1982

Ketoconazole in a case of chronic mucocutaneous candidiasis.

An 8-year-old girl with chronic mucocutaneous candidiasis was treated with Ketoconazole 100 mg daily for 6 weeks. Oral thrush disappeared after a week, while cutaneous lesions cleared within a month. Her nail dystrophy disappeared during the following months. Repeated cultures were negative for Candida albicans. The patient has remained in remission for an 8-month period. Our findings thus support previous reports indicating that Ketoconazole is an effective agent against this disease.

Antifungal Agents↗
PubMed1982

Ketoconazole in Trichophyton rubrum.

10 patients with T. rubrum infection were treated with Ketoconazole 200-400 mg a day for 8 weeks. All patients had a skin infection and 2 in addition infection of the toe nails. Previous treatment with Griseofulvin and at least two different antifungal topicals had been ineffective. The infection was evaluated by clinical findings and mycological examination. The skin lesions disappeared in 6 patients, while none of the nail lesions were cured. However, at a follow-up 2 months after the end of the Ketonocazole treatment, recurrence was observed in 3 of 6 patients. It is suggested that Ketoconazole treatment of previously resistant T. rubrum infection should be continued for more than 2 months.

Adult↗
PubMed1980

Oral sodium cromoglycate in chronic urticaria.

Fifteen patients were included in a double-blind cross-over trial to investigate the efficacy of oral sodium cromoglycate in the treatment of chronic urticaria. Only patients with positive oral provocation tests were entered into the study. The challenging agents were food additives or antirheumatic agents. Treatments were taken for 4 weeks and the dose of sodium cromoglycate was 200 mg four times daily. No significant differences were found between active and placebo treatment periods for diary card symptom scores. Six patients preferred the active treatment, two preferred placebo and seven had no preference. The clinician showed no preference for either treatment.

Administration, Oral↗
PubMed1975

Topical treatment with urea-hydrocortisone in atopic dermatitis. A controlled study against betamethasone 17-valerate.

When comparing 1% hydrocortisone in a stabilized 10% urea cream with 0.1% betamethasone 17-valerate cream in a double-blind study on 49 patients with atopic dermatitis or atopic winter feet, betamethasone cream was found to be the most potent. The study also showed that in approximately 60% of the patients the clinical response was equal. It is suggested that the urea-hydrocortisone combination may have its place in the long-term topical treatment of atopic dermatitis on account of its water-binding effect.

Administration, Topical↗